Event snippet :
top of page
  • Writer's pictureRachel O'Reilly

Aalto Bio Reagents Launches Yellow Fever Monoclonal Antibodies for Diagnostic Testing

Dublin, Ireland – January 31st, 2017 – Aalto Bio Reagents today announced the availability of their Yellow Fever monoclonal antibodies for diagnostic test manufacturers, vaccine developers and researchers globally. These monoclonal antibodies are raised against cell-culture derived viral lysate from strain 17D. Yellow Fever is the next flavivirus threatening the population of Brazil, with local health officials reporting a sharp rise in cases this year. International media last week reported that the Brazilian health authorities ordered 11.5 million doses of Yellow Fever vaccine amid the largest outbreak of the virus in the country since 2000. Recent outbreaks of Yellow Fever in Angola and the Republic of Congo have also been documented.

Yellow Fever, a potentially fatal mosquito-borne flavivirus, is common in tropical and subtropical locations in South America and Africa. Like other flaviruses such as Zika and Dengue virus, transmission to humans is predominantly via the female Aedes aegypti mosquito. There is no specific treatment for Yellow Fever and, despite access to safe and effective Yellow Fever vaccines; the virus is still causing significant health problems in these countries.

For many infectious diseases, serology assays are the preferred method of patient testing; however, for this sinister virus, early detection is critical to containing the spread of disease. Approximately 15% of infected patients enter what is known as the toxic phase, and this can lead to severe complications such as jaundice, multi-organ failure and even death. Research shows that Yellow Fever virus antigen is present in patients’ blood during the acute phase of illness. For that reason, Aalto Bio is launching its new Yellow Fever monoclonal antibodies which have been proven to detect Yellow Fever NS1 protein. These antibodies are unique in that they show no cross-reactivity with other flavivirus NS1 proteins, allowing very specific detection.

Philip Noone, CEO of Aalto Bio Reagents, said “Complementing our portfolio of recombinant proteins and antibodies for Chikungunya, Dengue and Zika virus with the Yellow Fever antibodies provides our clients with a one-stop-shop to a comprehensive suite of products for diagnostic testing. Early diagnosis of these viruses is key to managing cross-contamination and the spread of disease. We will continue to focus on the expansion of our tropical disease products to enable our customers to bring superior, best-in-class diagnostic products to market faster, and aid in the development of life-saving vaccines.”


About Aalto Bio Reagents

Founded in 1978, Aalto Bio Reagents is a leading developer and provider of raw materials to the in-vitro diagnostics industry and to research laboratories globally. We serve the largest multinational companies in our industry with a broad range of purified human proteins; monoclonal and polyclonal antibodies; fungal, parasitic, bacterial and viral antigens; and disease state plasma for in-vitro diagnostic application.

Since the company's inception, we have built strong working relationships with our clients who trust us to provide them with the highest quality raw materials to meet the exacting standards of their own product development requirements. Headquartered in Dublin, Ireland, the company is rapidly expanding both its product portfolio and customer base.

For further information please visit http://www.aaltobioreagents.com

Contact: Technical Sales Tel: +353-1-4900685 Email: info@aaltobioreagents.com

53 views0 comments
bottom of page